Navigation Links
ARRAYit Corporation Receives Purchase Order from ChemBio
Date:11/1/2013

SUNNYVALE, Calif., Nov. 1, 2013 /PRNewswire/ -- ARRAYit Corporation (OTCQB: ARYC) reports that it has received a $72,297 purchase order from ChemBio, the company's high-powered distributor in Moscow, Russia. ChemBio, which is Russia's premiere distributor of life sciences products and services, represents ARRAYit, Corning, Molecular Devices, Nalgene and other leading corporations, providing Russian customers with market information, technical assistance, installation, product support and training. 

ChemBio purchased the patented and proprietary ARRAYit Microarray Platform including a SpotBot® 3 Protein Edition Desktop Personal Microarrayer and 126 additional instruments, tools, kits, reagents and consumables for advanced microarray research and development. 

ARRAYit currently has a worldwide installed customer base of over 390 SpotBot® instruments, representing $8 million in aggregate revenue to the company. ARYC expects to report the sales and earnings from the ChemBio transaction in the current quarter. 

About ARRAYit Corporation                           

ARRAYit Corporation is a Sunnyvale, California-based company leading and empowering the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development, and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. The company's innovative products and services help scientists and clinicians explore the human genome as well as the genomes of plants and animals. ARRAYit's products are used by nearly every major research center in the world.

About Liston Street Pulse                                                

Liston Street Pulse is a leading provider of financial research. The company has significant expertise in U.S. listed small cap and micro-cap stocks. Subscribe here to read more about ARYC, including CEO interviews.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against ARRAYit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2012 and Form 10-Q for the fiscal first quarter ended March 31, 2013, Form 10-Q for the fiscal second quarter ended June 30, 2013.


'/>"/>
SOURCE ARRAYit Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arrayit Corporation Holds Successful Meeting with DHK Medical Products CEO
2. Arrayit on Major Fundraising Drive
3. Genentech Purchases Arrayit Technology
4. ARRAYit Corporation Ships Proprietary Life Sciences Products to Illumina Inc.
5. ARRAYit Corporation Ships Proprietary Life Sciences Products to Google Inc.
6. ARRAYit Corporation Receives $104,000 Purchase Order from the University of California
7. Arrayit Corporation Announces New Corporate Headquarters in Sunnyvale California
8. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
9. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
10. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
11. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
Breaking Medicine Technology:
(Date:4/22/2017)... , ... April 22, 2017 ... ... of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its “Woman-Owned ... PROSHRED® Philadelphia specializes in providing information destruction , recycling, and ...
(Date:4/21/2017)... , ... April 21, 2017 , ... An April 10 ... a pair of ancient teeth, which reveal a great deal about prehistoric ice-age dental ... sharp stone may have been used to remove decayed dental matter, and that teeth ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. ... osteoma is a benign bony lump located on the forehead usually attributed to a ... with sight and pain. Dr. Shah has discovered an approach that is minimally invasive. ...
(Date:4/21/2017)... ... 21, 2017 , ... Dudnyk has announced the launch of its new brand ... full potential of specialty and orphan brands can only be achieved when the needs ... Unifying Effect is at the heart of a true partnership between our agency and ...
(Date:4/21/2017)... ... , ... The Hong Kong Polytechnic University (PolyU) launched today the University Research ... in Hong Kong to support teaching, learning and research. It is also the largest ... in Hong Kong. , With an area of 620 square metres and more ...
Breaking Medicine News(10 mins):